Paul Tudor Jones's MRK Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 787,366 shares of Merck & Co., Inc. (MRK) worth $66.08 M, representing 0.11% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 45 quarters.
Based on 13F filings since 2013, Paul Tudor Jones has maintained a long-term strategic position in MRK, representing a significant commitment to this investment thesis. Largest addition occurred in Q3 2025, adding 787,366 shares. Largest reduction occurred in Q2 2025, reducing 774,203 shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's Merck & Co (MRK) Holding Value Over Time
Track share changes against reported price movement
Quarterly Merck & Co (MRK) Trades by Paul Tudor Jones
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2013 | +480,090 | Add 0.00% | 480,089 | $44.32 |
| Q3 2013 | -480,089 | Sold Out | 0 | $0.00 |
| Q1 2014 | +5,277 | New Buy | 5,277 | $54.20 |
| Q2 2014 | +8,626 | Add 163.46% | 13,903 | $55.17 |
| Q3 2014 | +19,345 | Add 139.14% | 33,248 | $56.57 |
| Q4 2014 | +22,376 | Add 67.30% | 55,624 | $54.19 |
| Q1 2015 | +46,129 | Add 82.93% | 101,753 | $54.85 |
| Q2 2015 | -84,042 | Reduce 82.59% | 17,711 | $54.32 |
| Q3 2015 | +29,096 | Add 164.28% | 46,807 | $47.13 |
| Q4 2015 | -4,299 | Reduce 9.18% | 42,508 | $50.39 |
| Q1 2016 | +706,215 | Add 1661.37% | 748,723 | $50.49 |
| Q2 2016 | -744,636 | Reduce 99.45% | 4,087 | $55.05 |
| Q3 2016 | +638,127 | Add 15613.58% | 642,214 | $59.55 |
| Q4 2016 | -631,839 | Reduce 98.38% | 10,375 | $56.19 |
| Q1 2017 | +166,241 | Add 1602.32% | 176,616 | $60.63 |
| Q2 2017 | -167,247 | Reduce 94.70% | 9,369 | $61.16 |
| Q3 2017 | -9,369 | Sold Out | 0 | $0.00 |
| Q4 2017 | +18,647 | New Buy | 18,647 | $53.68 |
| Q1 2018 | +48,417 | Add 259.65% | 67,064 | $51.98 |
| Q2 2018 | -67,064 | Sold Out | 0 | $0.00 |
| Q2 2019 | +9,165 | New Buy | 9,165 | $79.98 |
| Q3 2019 | -9,165 | Sold Out | 0 | $0.00 |
| Q4 2019 | +89,865 | New Buy | 89,865 | $86.79 |
| Q1 2020 | -61,130 | Reduce 68.02% | 28,735 | $73.43 |
| Q2 2020 | +31,315 | Add 108.98% | 60,050 | $73.79 |
| Q3 2020 | -47,502 | Reduce 79.10% | 12,548 | $79.14 |
| Q4 2020 | +14,833 | Add 118.21% | 27,381 | $78.05 |
| Q1 2021 | -27,381 | Sold Out | 0 | $0.00 |
| Q2 2021 | +15,544 | New Buy | 15,544 | $77.78 |
| Q3 2021 | -15,544 | Sold Out | 0 | $0.00 |
| Q4 2021 | +43,699 | New Buy | 43,699 | $76.64 |
| Q1 2022 | -39,080 | Reduce 89.43% | 4,619 | $82.05 |
| Q2 2022 | -4,619 | Sold Out | 0 | $0.00 |
| Q3 2022 | +9,243 | New Buy | 9,243 | $86.12 |
| Q4 2022 | -9,243 | Sold Out | 0 | $0.00 |
| Q1 2023 | +39,331 | New Buy | 39,331 | $0.11 |
| Q2 2023 | -39,331 | Sold Out | 0 | $0.00 |
| Q3 2023 | +84,792 | New Buy | 84,792 | $102.95 |
| Q4 2023 | -84,792 | Sold Out | 0 | $0.00 |
| Q2 2024 | +43,375 | New Buy | 43,375 | $123.80 |
| Q3 2024 | +125,129 | Add 288.48% | 168,504 | $113.56 |
| Q4 2024 | -117,676 | Reduce 69.84% | 50,828 | $99.48 |
| Q1 2025 | +723,375 | Add 1423.18% | 774,203 | $89.76 |
| Q2 2025 | -774,203 | Sold Out | 0 | $0.00 |
| Q3 2025 | +787,366 | New Buy | 787,366 | $83.93 |
Paul Tudor Jones's Merck & Co Investment FAQs
Paul Tudor Jones first purchased Merck & Co., Inc. (MRK) in Q2 2013, acquiring 480,089 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held Merck & Co., Inc. (MRK) for 45 quarters since Q2 2013.
Paul Tudor Jones's largest addition to Merck & Co., Inc. (MRK) was in Q3 2025, adding 787,366 shares worth $66.08 M.
According to the latest 13F filing for Q3 2025, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 787,366 shares of Merck & Co., Inc. (MRK), valued at approximately $66.08 M.
As of the Q3 2025 filing, Merck & Co., Inc. (MRK) represents approximately 0.11% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings.
Paul Tudor Jones's peak holding in Merck & Co., Inc. (MRK) was 787,366 shares, as reported at the end of Q3 2025.